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Introduction
Obesity is an epidemic (1). An increase in body fat
in many individuals and populations directly
increases the risk of metabolic diseases such as type 2
diabetes mellitus (T2DM), hypertension and dyslip-
idaemia (2). These are the most common metabolic
diseases encountered in endocrine practice, and
might also be considered epidemics. However, obes-
ity itself is not yet universally recognised as a disease
(3). A sole focus on body mass index (BMI) in
attempting to deﬁne obesity as a disease is not ade-
quate (4). A more rational approach is to evaluate
excessive body fat for its pathogenic potential. This
requires recognising that adipose tissue is an active
endocrine and immune organ (5), and that patholog-
ical disruption of important adipose tissue metabolic
processes is detrimental to patient health.
Anatomically, positive caloric balance may lead to
adipocyte hypertrophy and visceral adipose tissue
accumulation, which are well-known contributors to
metabolic disease (3,6). Conversely, weight loss inter-
ventions often help correct adipocyte and adipose
tissue endocrine and immune abnormalities in over-
weight patients. This may lead to improvement in
multiple metabolic parameters (7), often representing
an effective therapy towards treatment of metabolic
diseases such as T2DM, hypertension and dyslipid-
aemia (8).
The failure to adequately recognise the physiologic
importance of adipose tissue to metabolic health,
both clinically and in the medical⁄endocrine litera-
ture, is signiﬁcantly because of a failure of existing
terminology to adequately describe the pathogenic
potential of adipose tissue, and its contribution to
metabolic disease. An organ is often considered ‘dis-
eased’ if it undergoes anatomic abnormalities associ-
ated with physiological dysfunction that ultimately
lead to unfavourable health consequences. ‘Adipos-
opathy’ (adipose-opathy) is a term used to describe
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SUMMARY
Objective: To review current consensus and controversy regarding whether obesity
is a ‘disease’, examine the pathogenic potential of adipose tissue to promote met-
abolic disease and explore the merits of ‘adiposopathy’ and ‘sick fat’ as scientiﬁ-
cally and clinically useful terms in deﬁning when excessive body fat may represent
a ‘disease’. Methods: A group of clinicians and researchers, all with a back-
ground in endocrinology, assembled to evaluate the medical literature, as it per-
tains to the pathologic and pathogenic potential of adipose tissue, with an
emphasis on metabolic diseases that are often promoted by excessive body weight.
Results: The data support pathogenic adipose tissue as a disease. Challenges
exist to convince many clinicians, patients, healthcare entities and the public that
excessive body fat is often no less a ‘disease’ than the pathophysiological conse-
quences related to anatomical abnormalities of other body tissues. ‘Adiposopathy’
has the potential to scientiﬁcally deﬁne adipose tissue anatomic and physiologic
abnormalities, and their adverse consequences to patient health. Adiposopathy
acknowledges that when positive caloric balance leads to adipocyte hypertrophy
and visceral adiposity, then this may lead to pathogenic adipose tissue metabolic
and immune responses that promote metabolic disease. From a patient perspec-
tive, explaining how excessive caloric intake might cause fat to become ‘sick’ also
helps provide a rationale for patients to avoid weight gain. Adiposopathy also bet-
ter justiﬁes recommendations of weight loss as an effective therapeutic modality to
improve metabolic disease in overweight and obese patients. Conclusion: Adipos-
opathy (sick fat) is an endocrine disease.
What’s known
Excessive adipose tissue is generally accepted as a
‘‘cause’’ of clinical pathology related to its mass
effects, including various cardiovascular, neurologic,
pulmonary, musculoskeletal, dermatologic,
gastrointestinal, genitourinary, renal, and
psychological diseases.
What’s new
It is less recognized, and sometimes disputed, that
adipocyte hypertrophy and visceral adiposity may
contribute (‘‘cause’’) metabolic diseases such as
type 2 diabetes mellitus, hypertension, and
dyslipidemia. Adiposopathy and ‘‘sick fat’’ are
scientiﬁc and clinical terms, respectively, that help
deﬁne when excessive body fat is a metabolic
disease.
doi: 10.1111/j.1742-1241.2008.01848.x
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quences of pathogenic adipose tissue. From a patient
standpoint, the term adiposopathy can be translated
as representing ‘sick fat’ (9). These terms and this
approach emphasise that adipose tissue has as much
pathogenic potential to result in ill health as the
pathologic dysfunction of other body tissues. Thus,
‘adiposopathy’ represents a ‘disease’ similar to other
organopathies.
Adiposopathy and metabolic disease
Adiposopathy is a disease characterised by patho-
genic adipose tissue that is promoted by positive
caloric balance and sedentary lifestyle in genetically
and environmentally susceptible patients. Adiposopa-
thy is anatomically manifested by adipocyte hyper-
trophy, visceral adiposity and⁄or ectopic fat
deposition, which physiologically results in adverse
endocrine and immune consequences leading to met-
abolic disease. During positive caloric balance, initial
adipocyte hypertrophy optimally signals the recruit-
ment, proliferation and differentiation of additional
adipocytes in order to store energy (as fat) while
maintaining normal adipose tissue functionality.
However, if excessive fat cell enlargement occurs,
such as when adipogenesis is impaired, then derange-
ments of adipocyte (10) and adipose tissue metabolic
and immune responses may lead to metabolic disease
(Figure 1) (3).
Similarly, if positive caloric balance results in vis-
ceral adipose tissue accumulation, then this may also
contribute to metabolic disease (Figure 1). Thus, it is
not necessarily the increase in fat mass alone that
leads to metabolic disease. Rather it is adipocyte
hypertrophy and visceral adipose tissue adiposity that
represents the pathologic anatomic abnormalities
most likely to result in adverse metabolic conse-
quences to patients (Figure 2).
The determination as to when positive caloric bal-
ance may lead to adipocyte hypertrophy and visceral
adiposity is largely dependent upon underlying
genetics and the surrounding metabolic environment
(3). For example, obesity markedly increases the risk
of T2DM among Pima Indians. Positive caloric bal-
ance often leads to hypertrophied adipocytes in this
population, and the presence of anatomically larger
adipocytes is a better predictor of the onset of
T2DM, compared with obesity alone (11). Asian
Indians often have an anatomically pathogenic adi-
pose tissue presentation of increased adipocyte size
and visceral adipose tissue accumulation, along with
the pathophysiological metabolic and immune conse-
quences of increased circulating free fatty acids,
increased leptin, increased pro-inﬂammatory factors
and decreased anti-inﬂammatory factors. As a result,
they often have increased insulin resistance, T2DM
and dyslipidaemia, as well as an increased risk of
atherosclerotic coronary heart disease (CHD) (3).
Hypercortisolaemia may reduce the size of adipocytes
in peripheral, subcutaneous adipose tissue; but
increase the relative, and possibly absolute accumula-
tion of visceral adipose tissue. When coupled with a
glucocorticoid-induced increase in appetite, hepatic
gluconeogenesis and insulin resistance, this may all
contribute to adverse metabolic and inﬂammatory
adipose tissue responses that contribute to hyper-
glycaemia (3).
Another important determinant of the pathogenic
potential of adipose tissue involves crosstalk and
interactions with other body tissues. In fact, the
degree by which pathogenic adipose tissue may ulti-
mately result in metabolic disease is best considered
a net pathologic partnership with limitations and⁄or
dysfunction of other body organs. Disruption of bio-
logical signalling exchanges between adipose tissue
and adjacent adipocytes, as well as impaired ‘cros-
stalk’ with the nervous system, immune system, skel-
etal muscle, cardiovascular system, liver,
gastrointestinal system, adrenal cortex and thyroid,
may all contribute to pathogenic endocrinologic and
immune responses that contribute to metabolic dis-
ease (3). Additionally, the degree to which adipose
tissue may contribute to metabolic disease is largely
dependent upon the functionality of other non-adi-
pose body organs. In one illustrative example, if adi-
posopathy results in the net release of excessive free
fatty acids, then patients who have limitations in
their ability to oxidise intramuscular fat or intrahe-
patic free fatty acids may be particularly predisposed
to accumulate and store excessive triglycerides (3,12).
This ectopic fat deposition may prove to be ‘lipotox-
ic’ to these organs and contribute to diabetes mell-
itus and dyslipidaemia (13). In summary, fat weight
gain leading to metabolic disease is most dependent
upon how fat is stored (adipocyte hypertrophy vs.
adipocyte proliferation), where the fat is stored (vis-
ceral vs. other fat depots), and adipose tissue signal-
ling and interactions with other body organs.
Metabolic diseases most associated with adiposop-
athy include T2DM, hypertension and dyslipidaemia;
but may also include the metabolic syndrome, hyper-
androgenemia in women and hypoandrogenemia⁄
hyperestrogenemia in men (6). Adiposopathy may
also directly contribute to atherosclerosis (6). The
underlying manner and mechanisms whereby adipos-
opathy contributes to these metabolic diseases has
been described in detailed elsewhere (3,6–8). But
in general, these pathogenic mechanisms include
impaired adipogenesis, visceral adiposity, increased
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endocrine and inﬂammatory responses, and impaired
crosstalk and⁄or impaired interactions with other
body tissues (Table 1).
Responses to challenges and claims
regarding adiposopathy as a ‘disease’
Since 2006, through meetings, teleconferences and
emails, the authors have discussed and documented
various challenges and claims regarding the premise
that adiposopathy is a reasonable term to describe
pathogenic adipose tissue as a disease. ‘Real life’
speciﬁc challenges and claims listed below are
derived from journal reviewer comments of publi-
cations previously published by the authors (3,7),
and spirited correspondences and conversations
with colleagues. In general, it is the experience of
the authors that much disagreement exists
regarding the most basic assertion that pathogenic
Figure 1 Anatomic manifestations of adiposopathy include adipocyte hypertrophy and visceral adiposity, which may lead to
pathogenic metabolic and immune responses that promote metabolic disease (8). Positive caloric balance results in increased
energy storage, which is initially manifested by mild adipocyte hypertrophy. This normally promotes paracrine signalling for
adipogenesis (recruitment of new fat cells). Particularly when adipogenesis is impaired (3), continued positive caloric balance
may worsen adipocyte hypertrophy, causing adipocytes to become dysfunctional and potentially pathogenic. Similarly, if
excessive calories are stored in the visceral region, then this also is potentially pathogenic, and promotes metabolic disease.
Excessive body fat may not be ‘healthy’ because of pathologic mass effects. However, accumulation of adipose tissue through
adipocyte proliferation in the subcutaneous peripheral region may have less potential for promotion of metabolic disease,
and may therefore be metabolically ‘healthier’. If during weight loss, subcutaneous peripheral adipose tissue is diminished
and the proportion of visceral adipose tissue is increased, then this can also result in adiposopathy and promote metabolic
disease, as is found with some cases of hypercortisolaemia and human immunodeﬁciency virus-associated lipodystrophy.
Reproduced from Expert Rev. Cardiovasc. Ther. 4(6), 871–895 (2006) with permission of Expert Reviews Ltd
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ease. It is of interest that while many colleagues
engaged by the authors have expressed the opinion
that many of these premises are ‘self-evident,’ just
as many have an entirely opposing opinion that
these same premises have ‘yet to be proven.’ The
Figure 2 Adiposopathy is a disease that results in pathogenic metabolic and immune adipose tissue responses that promote metabolic disease (6).
Age, gender, race, and genetic predisposition, and sedentary lifestyle are all examples of determinants as to how positive caloric balance may lead to
adiposopathy. Pathogenic metabolic and immune responses associated with adiposopathy directly contribute to type 2 diabetes mellitus, hypertension,
dyslipidaemia and potentially atherosclerosis. Reproduced from Future Lipidol. (2006) 1(4), 389–420 with permission of Future Medicine
Table 1 Adiposopathy as a cause of metabolic disease: mechanistic supporting references (3,6–8)
Type 2 diabetes mellitus Hypertension Dyslipidaemia
Impaired adipogenesis (14–16) (17,18) (19)
Adipocyte hypertrophy (13,20,21) (22–24) (21)
Visceral adiposity (4,25,26) (27,28) (4,25)
Increased release of free fatty acids (13,29) (30,31) (32)
Endocrinopathies (33,34) (33,35) (33)
Inﬂammation (36–38) (39,40) (41)
Impaired ‘crosstalk’ or impaired interactions
with other body tissues
(42,43) (44,45) (46,47)
Positive caloric balance and sedentary lifestyle in genetically and environmentally susceptible patients leads to adipocyte hypertrophy
(sometimes promoted by impaired adipogenesis), visceral adiposity and⁄or ectopic fat deposition. These anatomic abnormalities often
result in pathophysiologic, adverse endocrine and immune consequences that lead to metabolic disease. Fat weight gain often results
in pathologic adipose tissue dysfunction, accounting for the onset or worsening of type 2 diabetes mellitus, hypertension, dyslipidaemia
and other metabolic disorders, which are the most common medical illnesses encountered in medical practice.
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with the authors’ responses:
Challenge 1: Metabolic activity of adipose
tissue
Claim: Excessive fat mass does not have the poten-
tial to be a ‘disease’ because adipose tissue is gen-
erally an inactive metabolic organ with clinically
insigniﬁcant endocrinologic and immunologic func-
tion.
Response: Adipose tissue is an active endocrine
organ (3,33). Adipose tissue is an active immune
organ (48). During times of positive caloric balance,
and in patients who are genetically and⁄or environ-
mentally predisposed, adipocyte hypertrophy and vis-
ceral adiposity may result in metabolic and immune
abnormalities that directly contribute to metabolic
disease (Table 1) (3,6).
Challenge 2: Consistency in adipose tissue’s
pathogenic potential
Claim: Excessive adipose tissue does not have the
potential to be a disease because obesity does not
result in adverse metabolic consequences to all
patients.
Response: Excessive adipose tissue may not be
pathogenic in all patients. While many cases of obes-
ity are associated with a signiﬁcantly increased risk
of various cardiovascular diseases (CVD) and cancer,
and while combined overweight and obese patients
are at risk for increased mortality from T2DM and
kidney disease, many mildly to moderately over-
weight patients may have lower mortality risk from
non-cancerous, non-CVD causes (49). Some studies
even suggest that being overweight or obese provides
‘protection’ against atherosclerotic CHD (50). Over-
all, this suggests that functional adipose tissue, even
when excessive, may be metabolically beneﬁcial in
some cases. This has sometimes described as repre-
senting an ‘obesity paradox’ (50). This paradox is
largely resolved with an understanding that it is
when adipose tissue is pathogenic that it then con-
tributes to metabolic derangements. Adiposopathy
also resolves another paradox wherein adding more
functional adipocytes is employed as a therapeutic
strategy to improve metabolic diseases that may be
caused by excessive fat weight gain (Table 2). Peroxi-
some proliferator-activated receptor gamma agents
increase the recruitment and proliferation of pre-
adipocytes, and improve multiple metabolic parame-
ters. This helps account for their efﬁcacy in reducing
glucose levels, and in some cases, improving lipid
levels (3,7,13).
Challenge 3: Clinical importance of anatomic
abnormalities of adipose tissue
Claim: Adiposopathy does not have the potential to
be a useful scientiﬁc term because ‘disease’ is usually
characterised by anatomical abnormalities of a body
organ that leads to pathologic dysfunction, which in
turn results in adverse clinical consequences to
patients.
Response: During positive caloric balance, adverse
metabolic consequences can be mitigated if the stor-
age of excess energy is achieved through recruitment
and proliferation of smaller, more functional adipo-
cytes in peripheral, subcutaneous depots. Conversely,
an increase in adipocyte size and an increase in
Table 2 Examples of treatments for adiposopathy and their effects upon adipose tissue factors that may contribute to metabolic disease (7)
Intervention
May affect glucose metabolism, blood
pressure and lipid metabolism
May affect glucose
metabolism
May affect blood
pressure May affect lipid metabolism
Visceral
adipose
tissue
Free
fatty
acids Leptin Adiponectin
Tumour
necrosis
factor-a
Renin-angiotensin-
aldosterone
enzymes Androgens Oestrogens
Nutrition and physical activity ﬂﬂ ﬂ › ﬂ ﬂ ﬂ (women), › (men) ﬂ⁄– (men)
PPAR-c agonists
(pioglitazone, rosiglitazone)
ﬂ⁄– ﬂﬂ ⁄ – ›ﬂ – ﬂﬂ ⁄ – (men)
Orlistat ﬂﬂ ﬂ › ﬂ ? ﬂ (women) ?
Sibutramine ﬂﬂ ﬂ › ⁄ –? ? ﬂ (women) ?
Cannabinoid receptor antagonists* ﬂﬂ ﬂ › ﬂ ???
Adipocyte hypertrophy and visceral adiposity result in multiple metabolic derangements that may promote metabolic disease. Existing therapies that treat adiposopa-
thy (pathogenic adipose tissue), result in improvement in multiple adipose tissue metabolic parameters. This helps account for why adiposopathy treatments improve
type 2 diabetes mellitus, hypertension and dyslipidemia (8). *Not currently available in USA. › = increased; ﬂ = decreased; ? = unknown; – = neutral effect.
PPAR-c, peroxisome proliferator-activated receptor-c.
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ated with metabolic abnormalities (51). If adipogene-
sis becomes impaired (either through genetic
predisposition or environmental circumstances), then
excessive adipocyte hypertrophy may occur in order
to continue to store excess energy. It has been known
since the 1970s that adipocyte hypertrophy results in
pathogenic abnormalities that may lead to metabolic
disease (10). It has been known since the 1940s that
excessive visceral fat accumulation contributes to
metabolic disease (52). Finally, another anatomic
abnormality often associated with adipose tissue dys-
function is the deposition of ectopic fat, which may
be ‘lipotoxic’ to other body organs, and again, lead
to metabolic disease (13). Anatomically, adiposopa-
thy is characterised by adipocyte hypertrophy, vis-
ceral adipose tissue accumulation and ectopic fat
deposition. Thus, just as with other organ diseases,
adipocyte and adipose tissue anatomic abnormalities
are central to its pathogenic potential.
Challenge 4: Differing inherent adipose tissue
physiology based upon location
Claim: Adiposopathy does not have the potential to
be a useful scientiﬁc term because not all adipose tis-
sue is in the same location, and organs cannot
become ‘diseased’ if they are in varying locations.
Response: Skeletal, smooth and⁄or cardiac muscle
are examples of different muscle types located in dif-
ferent regions of the body. Each of these types of
muscle has different physiologies, and different path-
ogenic potentials. Myocyte and muscle organ ana-
tomic abnormalities may lead to disrupted
physiology and adverse clinical signs and symptoms
to patients. Muscle cell hypertrophy is an anatomic
abnormality found in with some types of muscular
dystrophies, and is a type of pathogenic ‘‘myopathy’’.
Similarly, adipose tissue is located in different loca-
tions, such as visceral, subcutaneous and perivascular
regions. Not unlike muscle, different types of adipose
tissue are widely distributed throughout the body,
and have different physiologies and different patho-
genic potentials, depending upon the depot. Thus,
the anatomic abnormalities associated with adipocyte
and adipose tissue, as described by the term ‘adipos-
opathy’, are potentially as much a ‘disease’ as with
the ‘opathies’ of other body organs.
Challenge 5: Differing pathogenic potential
of adipose tissue depots
Claim: Adiposopathy does not have the potential to
be a useful scientiﬁc term because it implies that dif-
ferent adipose tissues locations have the potential to
contribute to metabolic ill health, when it is only vis-
ceral adiposity that is ‘pathogenic.’ Subcutaneous
adipose tissue accumulation prevents metabolic dis-
ease, and is ‘protective’.
Response: Different fat depots inherently have dif-
ferent types and different degrees of metabolic activi-
ties (3,53). Accumulation and hypertrophy of visceral
adipose tissue is most associated with an increased
risk of metabolic disease (6). But the pathogenic
potential of adipose tissue is not limited to visceral
fat. Pericardial, perimuscular, perivascular, orbital
and paraosseal adipose tissue are examples of perior-
gan adipose tissues that also may have pathogenic
potential (54,55). Pericardial and perivascular adi-
pose tissue may be pathogenic, through an ‘outside
to inside’ model of atherosclerosis that directly pro-
motes CHD and peripheral vascular disease (55–58).
Although often considered ‘protective’, even subcuta-
neous adipose tissue can be pathogenic. For example,
subcutaneous adipocyte hypertrophy located in the
abdominal region may worsen metabolic disease
(3,11,59).
Hypertrophy of peripheral subcutaneous adipose
tissue may be pathogenic in other ways as well. Sub-
cutaneous adipose tissue is the major source of cir-
culating leptin (60). Leptin’s secretion is associated
more with adipocyte hypertrophy than with adipo-
cyte hyperplasia (61). Hyperleptinaemia contributes
to hypertension (62,63). Thus, excessive body fat
storage through subcutaneous adipocyte hypertrophy
may be pathogenic by promoting leptin-induced high
blood pressure, although other adipose tissue mecha-
nisms are likely involved as well (3,64). Another
manner in which subcutaneous adipose tissue has
pathogenic potential is in regard to free fatty acid
release. The majority of postabsorptive systemic free
fatty acids are derived from subcutaneous adipose
tissue (65,66). These fatty acids may be ‘lipotoxic’ to
muscle, pancreas and vasculature (65). Finally, it has
even been suggested that the pathogenic potential of
subcutaneous adipose tissue may sometimes be trig-
gered by the pathogenic effects of visceral adipose
tissue (65). Thus, the pathogenic potential of adipose
tissue is not limited to visceral accumulation. The
term ‘adiposopathy’ acknowledges this diversity in
adipose tissue’s pathogenic potential.
Challenge 6: Contribution of body organs,
other than adipose tissue, to metabolic disease
Claim: Adiposopathy does not have the potential to
be a disease because the metabolic diseases often
associated with obesity may signiﬁcantly be due to
the dysfunction of other body organs.
Response: The degree by which metabolic and
immune derangements of pathogenic adipose tissue
results in metabolic disease is dependent upon many
factors such as the level of physical activity, genetic
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(e.g. drug therapies, dysfunction of other body
organs, toxins, etc.). The response of other body
organs to these derangements determines if adipocyte
hypertrophy and visceral adiposity may ultimately
result in clinical, metabolic disease. The pathogenic
potential of adipose tissue is best viewed as a patho-
logic partnership with inherited or acquired limita-
tions in ‘crosstalk’ and⁄or impairments of other
body organs.
This type of relationship is neither novel nor
unique to adiposopathy. Hyperglycaemia does not
always result in acute or chronic diabetes complica-
tions; high blood pressure does not always result in
cardiovascular or renal disease; and hypercholestero-
laemia does not always result in clinical manifesta-
tions of atherosclerosis. Nonetheless, few would argue
that these metabolic abnormalities are not ‘diseases’,
or that somehow, the variabilities in clinical outcomes
negates the need for their diagnosis and treatment
(6). Instead, recommendations regarding diagnosis
and treatment often target those at highest risk for
adverse clinical outcomes as being the patients in
most need of aggressive management. Similarly, path-
ogenic adipose tissue may not always result in clinical
disease in all patients. Some patients may have sufﬁ-
cient inherent organ functionality (such as liver,
muscle and pancreas) that allows for a heightened
capacity to metabolise excessive free fatty acids and
appropriately manage potential pathogenic metabolic
and net pro-inﬂammatory adipocyte and adipose tis-
sue responses. Conversely, other patients may have
inherent [or acquired (67)] metabolic impairments of
muscle (12,47,68–70), liver (71) and⁄or pancreas
(72), such that they may be more susceptible to the
adverse clinical consequences of pathogenic adipose
tissue. Thus, just as with diabetes mellitus, hyperten-
sion and dyslipidaemia, pathogenic adipose tissue is a
disease process that results in adverse clinical mani-
festations when in partnership with other concomi-
tant facilitating factors. In the case of pathogenic
adipose tissue, not only do adipocyte hypertrophy,
visceral adiposity and ectopic fat deposition poten-
tially contribute to the dysfunction of end organs
such as liver, muscle and pancreas, but the inherited
and⁄or acquired limitations or dysfunctions of these
same end organs may exacerbate adiposopathy’s
potential to result in clinical metabolic disease.
Challenge 7: Adipose tissue and personal
behaviour
Claim: Adiposopathy cannot accurately be character-
ised as a ‘disease’ because excessive adipose tissue
leading to metabolic disease is often the result of
unfavourable personal behaviour whose effective
therapy is unlikely to be achieved through medical
science.
Response: Syphilis is a disease that periodically
arises as an ‘epidemic’ in impoverished areas with
lack of medical access, especially in patients with
lower educational background who exhibit unfavour-
able personal behaviour (73). Syphilis was one of the
leading causes of hopeless morbidity and mortality
in the beginning of the 20th century. Initially, the
cause was unknown and no diagnostic procedures or
treatment existed. Subsequently, the cause was found,
diagnostic criteria were established, and after 300
failures with other arsenical compounds, salvarsan
was found to an effective treatment (74). This ther-
apy has since been replaced by the even more effec-
tive treatment of penicillin.
Currently, many have little hope that an effective
treatment for the epidemic of obesity is imminent.
Diagnostic criteria for adiposopathy have yet to be
established. It is unknowable if future therapies will
be developed to treat pathogenic adipose tissue, with
the same degree of efﬁcacy as insulin in patients with
diabetes mellitus, diuretics for hypertension and sta-
tins for hypercholesterolaemia (75). As with other
metabolic diseases, combination therapies of agents
with complementary mechanisms of actions may
eventually be required in order to achieve optimal
therapeutic goals (75). Additionally, public health
factors must be overcome (73) in order to effectively
treat adiposopathy. Such initiatives include better
communication between healthcare providers and
their patients, improved education about the patho-
genic potential of adipose tissue (sick fat), imple-
mentation of more effective programmes to promote
these public health initiatives, and personal adoption
of more favourable nutritional and lifestyle habits.
From a pharmaceutical standpoint, few would
argue that penicillin should be withheld from syphilis
patients, irrespective of the degree to which unfa-
vourable personal behaviour contributes to acquiring
the disease. Similarly, while adiposopathy and its
adverse metabolic consequences are often promoted
by poor personal behaviour, it is nonetheless a dis-
ease that requires treatment. As has historically
occurred whenever faced with seemingly hopeless
epidemics, it is reasonable to believe that medical sci-
ence will ultimately prevail. More effective therapies
will be developed to effectively treat the epidemics of
adiposopathy and its metabolic consequences (7,75).
Challenge 8: Potential confusion in contrasting
obesity with adiposopathy
Claim: Adiposopathy detracts from the essential
message that excessive body fat is due to positive
caloric balance, and potentially results in obesity
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restricted to metabolic and immune abnormalities.
Excessive fat mass alone may cause adverse health
consequences to patients.
Response: The authors concurs with prior clinical
practice guidelines that call for the prevention and
treatment of obesity beyond the metabolic conse-
quences of adiposopathy, as excessive body fat mass
alone can cause cardiovascular, neurologic, pulmo-
nary, musculoskeletal, dermatologic, gastrointestinal,
genitourinary, renal and psychological diseases
(3,76,77). It is in these types of clinical presentations
wherein the term ‘obesity’ alone might best be con-
sidered an underlying cause of adverse health conse-
quences. However, it would be unreasonable to
conclude that medical science, clinicians and patients
are unable to comprehend the fundamental differ-
ence between the adverse physical health conse-
quences associated with an increase in adipose tissue
mass, and the adverse metabolic health consequences
associated with adipose tissue dysfunction. The fail-
ure to recognise what may be two distinct pathologic
entities may deny appropriate care to overweight and
obese patients.
For example, many morbidly obese patients seek
to treat their adiposity through surgical interven-
tions, especially when they suffer from obesity-
induced severe sleep apnoea, immobility, CVD and
other such medical disorders (78). Although many of
these surgical interventions may have a relatively
high complication rate, especially in the presence of
multiple comorbidities (79), they are often reim-
bursed through health insurance companies.
However, some patients with only mild increases
in body weight may develop metabolic abnormalities
that may place them at risk, or in fact cause diagnos-
able metabolic disease. This is one of the reasons
why Asians require different BMI cut-off points in
assessing their risk of metabolic disease (80). Because
of the lack of established diagnostic criteria for path-
ogenic adipose tissue, access to care for these patients
may be restricted because of a lack of third party
payer coverage. To deny that adiposopathy can occur
in even mildly overweight patients is to deny the
most appropriate treatment to individual patients,
and perhaps entire populations.
Challenge 9: Adiposopathy is a novel term
Claim: Adiposopathy is an unnecessary term that
does not aid clinicians in their assessment or treat-
ment of patients, and ‘sick fat’ is unlikely to improve
patient understanding of the relationship of excessive
body weight to metabolic disease, as exists with more
currently accepted terms such as the ‘metabolic syn-
drome’.
Response: The metabolic syndrome does not
describe, nor does it attempt to describe a uniﬁed,
underlying pathophysiologic process (81). In contrast,
adiposopathy acknowledges that duringpositive caloric
balance, adipose tissue may undergo pathogenic ana-
tomical, metabolic and immune responses that lead to
metabolic disease. From a practical standpoint, it
would be most beneﬁcial if clinicians could know
which patients have pathogenic adipose tissue, and
thus know which patients are most at risk for develop-
ing metabolic disease with weight gain. It would be of
equal beneﬁt to know which overweight patients
would most likely have improvement in their meta-
bolic disease with weight loss. Hence, it would be in
patients’ best interest for scientiﬁc organisations and
regulatory agencies establish diagnostic criteria for the
diagnosis of adiposopathy (9). Once diagnostic criteria
have been established, the next logical step would be
creation of indications for treatment of adiposopathy,
which in turn would treat important underlying causes
of the most common endocrine diseases encountered
in clinical practice (Table 2).
From a patient perspective, the term ‘sick fat’ is
both accurate and perhaps clinically useful. A discus-
sion as to how increasing body weight may cause their
fat to become ‘sick,’ or how losing body weight may
cause their fat to become more ‘healthy’, might be a
more fruitful discussion than discussing the diagnostic
components deﬁning the ‘metabolic syndrome (82)’.
Challenge 10: Adiposopathy is a ‘novel’
concept
Claim: Adiposopathy is not a potentially useful sci-
entiﬁc term because it emphasises the profound met-
abolic and immune pathogenic potential of adipose
tissue whose complexities will present an insur-
mountable educational challenge.
Response: Max Planck, founder of quantum phys-
ics, suggested in the mid-1900s: ‘A new scientiﬁc
truth does not triumph by convincing its opponents
and making them see the light, but rather because its
opponents eventually die, and a new generation
grows up that is familiar with it’ (81). His intent was
to describe his perception of the challenges associated
with scientiﬁc concepts not yet accepted by the scien-
tiﬁc establishment. Arthur Schopenhauer, a German
philosopher (1788–1860) is credited with saying that:
‘All truth passes through three stages. First, it is ridi-
culed. Second, it is violently opposed. Third, it is
accepted as being self-evident’. So, it may also be
that even some in the scientiﬁc community may be
resistant to the suggestion that pathogenic adipose
tissue is a disease. But in contrast to the scientiﬁc
establishment, it is simply a fact that clinicians often
see patients who are markedly overweight, yet have
Adiposopathy 1481
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patients who, upon gaining only modest body fat,
develop T2DM, hypertension and dyslipidaemia. For
many of them, ‘adiposopathy’ may prove to be a
welcomed term that better reﬂects their practical,
clinical experience regarding overweight patients.
‘Sick fat’ is a term that might better assist them in
educating their patients.
Conclusion
Adiposopathy is an endocrine disease.
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